Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities

Pharmacology and Therapeutics

Volumn 186, Issue , 2018, Pages 73-87

  Ong, Sang Bing ^a,b   Hernández Reséndiz, Sauri ^a,b   Crespo Avilan, Gustavo E ^a,b   Mukhametshina, Regina T ^g,h   Kwek, Xiu Yi ^a,b   Cabrera Fuentes, Hector A ^a,b,e,f,g   Hausenloy, Derek J ^a,b,c,d,i,j  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^g KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^h JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

more..

Author keywords

Acute myocardial infarction; Acute myocardial ischemia and reperfusion injury; Chemokines; Cytokines; Dendritic cells; Inflammation; Innate immunity; Lymphocytes; Macrophages; Monocytes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHEMOKINE; COMPLEMENT; CORTICOSTEROID; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; ANTIINFLAMMATORY AGENT; AUTACOID;

ACUTE HEART INFARCTION; CARDIAC MUSCLE CELL; CARDIAC PATIENT; CAUSE OF DEATH; DENDRITIC CELL; ENDOTHELIUM CELL; HEART DEATH; HEART FIBROBLAST; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RUPTURE; HUMAN; INNATE IMMUNITY; ISCHEMIC PRECONDITIONING; MACROPHAGE; MONOCYTE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NEUTROPHIL; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; WOUND HEALING; ANIMAL; DISEASE MODEL; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 85041589954     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2018.01.001     Document Type: Review

References (154)

1. Abbate, A., Kontos, M.C., Grizzard, J.D., Biondi-Zoccai, G.G., Van Tassell, B.W., Robati, R., et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study). The American Journal of Cardiology 105 (2010), 1371–1377, 10.1016/j.amjcard.2009.12.059 (S0002-9149(10)00066-4 [pii]).
2. Abbate, A., Salloum, F.N., Vecile, E., Das, A., Hoke, N.N., Straino, S., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117 (2008), 2670–2683, 10.1161/CIRCULATIONAHA.107.740233 (CIRCULATIONAHA.107.740233 [pii]).
3. Abbate, A., Van Tassell, B.W., Biondi-Zoccai, G., Kontos, M.C., Grizzard, J.D., Spillman, D.W., et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. The American Journal of Cardiology 111 (2013), 1394–1400, 10.1016/j.amjcard.2013.01.287 (S0002-9149(13)00383-4 [pii]).
4. Amsterdam, E.A., Stahl, G.L., Pan, H.L., Rendig, S.V., Fletcher, M.P., Longhurst, J.C., Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. The American Journal of Physiology 268 (1995), H448–H457.
5. Andrassy, M., Volz, H.C., Igwe, J.C., Funke, B., Eichberger, S.N., Kaya, Z., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117 (2008), 3216–3226, 10.1161/CIRCULATIONAHA.108.769331 (117/25/3216 [pii]).
6. Anzai, A., Anzai, T., Nagai, S., Maekawa, Y., Naito, K., Kaneko, H., et al. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation 125 (2012), 1234–1245, 10.1161/CIRCULATIONAHA.111.052126 (CIRCULATIONAHA.111.052126 [pii]).
7. Arai, M., Lefer, D.J., So, T., DiPaula, A., Aversano, T., Becker, L.C., An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. Journal of the American College of Cardiology 27 (1996), 1278–1285.
8. Armstrong, P.W., Granger, C.B., Adams, P.X., Hamm, C., Holmes, D. Jr., O'Neill, W.W., et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. JAMA 297 (2007), 43–51, 10.1001/jama.297.1.43 (297/1/43 [pii]).
9. Arslan, F., Houtgraaf, J.H., Keogh, B., Kazemi, K., de J, R., McCormack, W.J., et al. Treatment with OPN-305, a humanized anti-Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circulation. Cardiovascular Interventions 5 (2012), 279–287, 10.1161/CIRCINTERVENTIONS.111.967596 (CIRCINTERVENTIONS.111.967596 [pii]).
10. Arslan, F., Smeets, M.B., O'Neill, L.A., Keogh, B., McGuirk, P., Timmers, L., et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 121 (2010), 80–90, 10.1161/CIRCULATIONAHA.109.880187 (CIRCULATIONAHA.109.880187 [pii]).
11. Atar, D., Petzelbauer, P., Schwitter, J., Huber, K., Rensing, B., Kasprzak, J.D., et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. Journal of the American College of Cardiology 53 (2009), 720–729.
12. Aversano, T., Zhou, W., Nedelman, M., Nakada, M., Weisman, H., A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. Journal of the American College of Cardiology 25 (1995), 781–788.
13. Baran, K.W., Nguyen, M., McKendall, G.R., Lambrew, C.T., Dykstra, G., Palmeri, S.T., et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 104 (2001), 2778–2783.
14. Bliksoen, M., Mariero, L.H., Ohm, I.K., Haugen, F., Yndestad, A., Solheim, S., et al. Increased circulating mitochondrial DNA after myocardial infarction. International Journal of Cardiology 158 (2012), 132–134, 10.1016/j.ijcard.2012.04.047 (S0167-5273(12)00468-8 [pii]).
15. Boag, S.E., Das, R., Shmeleva, E.V., Bagnall, A., Egred, M., Howard, N., et al. T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients. The Journal of Clinical Investigation 125 (2015), 3063–3076, 10.1172/JCI80055 (80055 [pii]).
16. Briaud, S.A., Ding, Z.M., Michael, L.H., Entman, M.L., Daniel, S., Ballantyne, C.M., Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice. American Journal of Physiology. Heart and Circulatory Physiology 280 (2001), H60–H67.
17. Brunstein, C.G., Miller, J.S., Cao, Q., McKenna, D.H., Hippen, K.L., Curtsinger, J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117 (2011), 1061–1070, 10.1182/blood-2010-07-293795 (blood-2010-07-293795 [pii]).
18. Buerke, M., Prufer, D., Dahm, M., Oelert, H., Meyer, J., Darius, H., Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. The Journal of Pharmacology and Experimental Therapeutics 286 (1998), 429–438.
19. Bujak, M., Dobaczewski, M., Chatila, K., Mendoza, L.H., Li, N., Reddy, A., et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. The American Journal of Pathology 173 (2008), 57–67, 10.2353/ajpath.2008.070974 (S0002-9440(10)61585-4 [pii]).
20. Burchfield, J.S., Xie, M., Hill, J.A., Pathological ventricular remodeling: Mechanisms: Part 1 of 2. Circulation 128 (2013), 388–400, 10.1161/CIRCULATIONAHA.113.001878 (128/4/388 [pii]).
21. Busche, M.N., Pavlov, V., Takahashi, K., Stahl, G.L., Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. American Journal of Physiology. Heart and Circulatory Physiology 297 (2009), H1853–H1859, 10.1152/ajpheart.00049.2009 (00049.2009 [pii]).
22. Cabrera-Fuentes, H.A., Alba-Alba, C., Aragones, J., Bernhagen, J., Boisvert, W.A., Botker, H.E., et al. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: Between bench and bedside. Basic Research in Cardiology, 111, 2016, 7, 10.1007/s00395-015-0527-0 (10.1007/s00395-015-0527-0 [pii]).
23. Cabrera-Fuentes, H.A., Aragones, J., Bernhagen, J., Boening, A., Boisvert, W.A., Botker, H.E., et al. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: Meeting report from the third international symposium on “New frontiers in cardiovascular research”. Basic Research in Cardiology, 111, 2016, 69, 10.1007/s00395-016-0586-x (10.1007/s00395-016-0586-x [pii]).
24. Cabrera-Fuentes, H.A., Ruiz-Meana, M., Simsekyilmaz, S., Kostin, S., Inserte, J., Saffarzadeh, M., et al. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-alpha in cardiac ischaemia/reperfusion injury. Thrombosis and Haemostasis 112 (2014), 1110–1119, 10.1160/TH14-08-0703 (14-08-0703 [pii]).
25. Coll, R.C., Robertson, A.A., Chae, J.J., Higgins, S.C., Munoz-Planillo, R., Inserra, M.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 21 (2015), 248–255, 10.1038/nm.3806 (nm.3806 [pii]).
26. Courties, G., Heidt, T., Sebas, M., Iwamoto, Y., Jeon, D., Truelove, J., et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. Journal of the American College of Cardiology 63 (2014), 1556–1566, 10.1016/j.jacc.2013.11.023 (S0735-1097(13)06344-4 [pii]).
27. Cung, T.T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., et al. Cyclosporine before PCI in patients with acute myocardial infarction. The New England Journal of Medicine 373 (2015), 1021–1031, 10.1056/NEJMoa1505489.
28. de Zwaan, C., Kleine, A.H., Diris, J.H., Glatz, J.F., Wellens, H.J., Strengers, P.F., et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. European Heart Journal 23 (2002), 1670–1677 (S0195668X0293191X [pii]).
29. Dewald, O., Zymek, P., Winkelmann, K., Koerting, A., Ren, G., Abou-Khamis, T., et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circulation Research 96 (2005), 881–889, 10.1161/01.RES.0000163017.13772.3a (01.RES.0000163017.13772.3a [pii]).
30. Ding, H.S., Yang, J., Chen, P., Yang, J., Bo, S.Q., Ding, J.W., et al. The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis. Gene 527 (2013), 389–393, 10.1016/j.gene.2013.05.041 (S0378-1119(13)00677-X [pii]).
31. Dobaczewski, M., Xia, Y., Bujak, M., Gonzalez-Quesada, C., Frangogiannis, N.G., CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. The American Journal of Pathology 176 (2010), 2177–2187, 10.2353/ajpath.2010.090759 (S0002-9440(10)60014-4 [pii]).
32. Dorn, G.W., Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nature Reviews Cardiology 6 (2009), 283–291, 10.1038/nrcardio.2009.12 (nrcardio.2009.12 [pii]).
33. Empana, J.P., Jouven, X., Canoui-Poitrine, F., Luc, G., Tafflet, M., Haas, B., et al. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: The PRIME study. Arteriosclerosis, Thrombosis, and Vascular Biology 30 (2010), 2047–2052, 10.1161/ATVBAHA.110.208785 (ATVBAHA.110.208785 [pii]).
34. Engler, R., Covell, J.W., Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog 1. Circulation Research 61 (1987), 20–28.
35. Engler, R.L., Dahlgren, M.D., Morris, D.D., Peterson, M.A., Schmid-Schonbein, G.W., Role of leukocytes in response to acute myocardial ischemia and reflow in dogs 1. The American Journal of Physiology 251 (1986), H314–H323.
36. Engler, R.L., Dahlgren, M.D., Peterson, M.A., Dobbs, A., Schmid-Schonbein, G.W., Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia 1. The American Journal of Physiology 251 (1986), H93–100.
37. Fattouch, K., Bianco, G., Speziale, G., Sampognaro, R., Lavalle, C., Guccione, F., et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: A randomised double-blind study. European Journal of Cardio-Thoracic Surgery 32 (2007), 326–332, 10.1016/j.ejcts.2007.04.038 (S1010-7940(07)00436-8 [pii]).
38. Faxon, D.P., Gibbons, R.J., Chronos, N.A., Gurbel, P.A., Sheehan, F., The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. Journal of the American College of Cardiology 40 (2002), 1199–1204.
39. Ferdinandy, P., Hausenloy, D.J., Heusch, G., Baxter, G.F., Schulz, R., Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacological Reviews 66 (2014), 1142–1174, 10.1124/pr.113.008300 (66/4/1142 [pii]).
40. Frangogiannis, N.G., Mendoza, L.H., Lindsey, M.L., Ballantyne, C.M., Michael, L.H., Smith, C.W., et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. Journal of Immunology 165 (2000), 2798–2808 (ji_v165n5p2798 [pii]).
41. Fuchs, M., Hilfiker, A., Kaminski, K., Hilfiker-Kleiner, D., Guener, Z., Klein, G., et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. The FASEB Journal 17 (2003), 2118–2120, 10.1096/fj.03-0331fje (03-0331fje [pii]).
42. Garcia, R.A., Go, K.V., Villarreal, F.J., Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Molecular and Cellular Biochemistry 300 (2007), 159–169, 10.1007/s11010-006-9379-0.
43. Gorsuch, W.B., Guikema, B.J., Fritzinger, D.C., Vogel, C.W., Stahl, G.L., Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Molecular Immunology 47 (2009), 506–510, 10.1016/j.molimm.2009.08.017 (S0161-5890(09)00687-7 [pii]).
44. Granger, C.B., Mahaffey, K.W., Weaver, W.D., Theroux, P., Hochman, J.S., Filloon, T.G., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108 (2003), 1184–1190.
45. Gwechenberger, M., Mendoza, L.H., Youker, K.A., Frangogiannis, N.G., Smith, C.W., Michael, L.H., et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99 (1999), 546–551.
46. Hammerman, H., Kloner, R.A., Hale, S., Schoen, F.J., Braunwald, E., Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation 68 (1983), 446–452.
47. Hanna, R.N., Carlin, L.M., Hubbeling, H.G., Nackiewicz, D., Green, A.M., Punt, J.A., et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nature Immunology 12 (2011), 778–785, 10.1038/ni.2063 (ni.2063 [pii]).
48. Harel-Adar, T., Ben, M.T., Amsalem, Y., Feinberg, M.S., Leor, J., Cohen, S., Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proceedings of the National Academy of Sciences of the United States of America 108 (2011), 1827–1832, 10.1073/pnas.1015623108 (1015623108 [pii]).
49. Hartman, M.H., Vreeswijk-Baudoin, I., Groot, H.E., van de Kolk, K.W., de Boer, R.A., Mateo, L.I., et al. Inhibition of Interleukin-6 receptor in a murine model of myocardial ischemia-reperfusion. PLoS One, 11, 2016, e0167195, 10.1371/journal.pone.0167195 (PONE-D-16-01430 [pii]).
50. Hausenloy, D.J., Botker, H.E., Engstrom, T., Erlinge, D., Heusch, G., Ibanez, B., et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: Trials and tribulations. European Heart Journal 38 (2017), 935–941, 10.1093/eurheartj/ehw145 (ehw145 [pii]).
51. Hausenloy, D.J., Garcia-Dorado, D., Botker, H.E., Davidson, S.M., Downey, J., Engel, F.B., et al. Novel targets and future strategies for acute cardioprotection: Position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research 113 (2017), 564–585, 10.1093/cvr/cvx049 (3074260 [pii]).
52. Hayashidani, S., Tsutsui, H., Shiomi, T., Ikeuchi, M., Matsusaka, H., Suematsu, N., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108 (2003), 2134–2140, 10.1161/01.CIR.0000092890.29552.22 (01.CIR.0000092890.29552.22 [pii]).
53. Hilgendorf, I., Gerhardt, L.M., Tan, T.C., Winter, C., Holderried, T.A., Chousterman, B.G., et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circulation Research 114 (2014), 1611–1622, 10.1161/CIRCRESAHA.114.303204 (CIRCRESAHA.114.303204 [pii]).
54. Hofmann, U., Beyersdorf, N., Weirather, J., Podolskaya, A., Bauersachs, J., Ertl, G., et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation 125 (2012), 1652–1663, 10.1161/CIRCULATIONAHA.111.044164 (CIRCULATIONAHA.111.044164 [pii]).
55. Homma, T., Kinugawa, S., Takahashi, M., Sobirin, M.A., Saito, A., Fukushima, A., et al. Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice. Journal of Molecular and Cellular Cardiology 62 (2013), 179–188, 10.1016/j.yjmcc.2013.06.004 (S0022-2828(13)00203-4 [pii]).
56. Hu, G., Zhang, Y., Jiang, H., Hu, X., Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression. Cardiology Journal 20 (2013), 600–604, 10.5603/CJ.2013.0159 (VM/OJS/J/36493 [pii]).
57. Huang, Y., Wang, D., Wang, X., Zhang, Y., Liu, T., Chen, Y., et al. Abrogation of CC chemokine receptor 9 ameliorates ventricular remodeling in mice after myocardial infarction. Scientific Reports, 6, 2016, 32660, 10.1038/srep32660 (srep32660 [pii]).
58. Iyer, S.S., He, Q., Janczy, J.R., Elliott, E.I., Zhong, Z., Olivier, A.K., et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 39 (2013), 311–323, 10.1016/j.immuni.2013.08.001.
59. Jones, S.P., Tang, X.L., Guo, Y., Steenbergen, C., Lefer, D.J., Kukreja, R.C., et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): A new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circulation Research 116 (2015), 572–586, 10.1161/CIRCRESAHA.116.305462 (CIRCRESAHA.116.305462 [pii]).
60. Jong, W.M., Ten, C.H., Linnenbank, A.C., de Boer, O.J., Reitsma, P.H., de Winter, R.J., et al. Reduced acute myocardial ischemia-reperfusion injury in IL-6-deficient mice employing a closed-chest model. Inflammation Research 65 (2016), 489–499, 10.1007/s00011-016-0931-4 (10.1007/s00011-016-0931-4 [pii]).
61. Jordan, J.E., Montalto, M.C., Stahl, G.L., Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104 (2001), 1413–1418.
62. Jugdutt, B.I., Khan, M.I., Jugdutt, S.J., Blinston, G.E., Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. Circulation 91 (1995), 802–812.
63. Kaminski, K.A., Kozuch, M., Bonda, T.A., Stepaniuk, M.M., Waszkiewicz, E., Chyczewski, L., et al. Effect of interleukin 6 deficiency on the expression of Bcl-2 and Bax in the murine heart. Pharmacological Reports 61 (2009), 504–513.
64. Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123 (2011), 594–604, 10.1161/CIRCULATIONAHA.110.982777 (CIRCULATIONAHA.110.982777 [pii]).
65. Ke, D., Fang, J., Fan, L., Chen, Z., Chen, L., Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Coronary Artery Disease 24 (2013), 334–341, 10.1097/MCA.0b013e3283608c12.
66. Kirlin, P.C., Romson, J.L., Pitt, B., Abrams, G.D., Schork, M.A., Lucchesi, B.R., Ibuprofen-mediated infarct size reduction: Effects on regional myocardial function in canine myocardial infarction in canine myocardial infarction. The American Journal of Cardiology 50 (1982), 849–856.
67. Kitahara, T., Takeishi, Y., Harada, M., Niizeki, T., Suzuki, S., Sasaki, T., et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovascular Research 80 (2008), 40–46 (cvn163 [pii]) https://doi.org/10.1093/cvr/cvn163.
68. Kleveland, O., Kunszt, G., Bratlie, M., Ueland, T., Broch, K., Holte, E., et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial. European Heart Journal 37 (2016), 2406–2413, 10.1093/eurheartj/ehw171 (ehw171 [pii]).
69. Kloner, R.A., Forman, M.B., Gibbons, R.J., Ross, A.M., Alexander, R.W., Stone, G.W., Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: The AMISTAD-2 trial. European Heart Journal 27 (2006), 2400–2405.
70. Ku, S.H., Hong, J., Moon, H.H., Jeong, J.H., Mok, H., Park, S., et al. Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. Archives of Pharmacal Research 38 (2015), 1317–1324, 10.1007/s12272-014-0527-x.
71. Kukreja, R., Tang, X.-L., Lefer, D., Steenbergen, C., Jones, S., Guo, Y., et al. Administration of Sildenafil at reperfusion fails to reduce infarct size: Results from the CAESAR Cardioprotection Consortium. The FASEB Journal, 28, 2014, LB650 (Ref Type: Abstract).
72. Kumar, A.G., Ballantyne, C.M., Michael, L.H., Kukielka, G.L., Youker, K.A., Lindsey, M.L., et al. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation 95 (1997), 693–700.
73. Lecour, S., Botker, H.E., Condorelli, G., Davidson, S.M., Garcia-Dorado, D., Engel, F.B., et al. ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies. Cardiovascular Research 104 (2014), 399–411, 10.1093/cvr/cvu225 (cvu225 [pii]).
74. Lefer, D.J., Bolli, R., Development of an NIH Consortium for preclinicAl AssESsment of cARdioprotective therapies (CAESAR): A paradigm shift in studies of infarct size limitation. Journal of Cardiovascular Pharmacology and Therapeutics 16 (2011), 332–339, 10.1177/1074248411414155 (16/3-4/332 [pii]).
75. Lefer, D., Jones, S., Steenbergen, C., Kukreja, R., Guo, Y., Tang, X.-L., et al. Sodium nitrite fails to limit myocardial infarct size: Results from the CAESAR Cardioprotection Consortium. The FASEB Journal, 28, 2014, LB645.
76. Lefer, D.J., Shandelya, S.M., Serrano, C.V. Jr., Becker, L.C., Kuppusamy, P., Zweier, J.L., Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation 88 (1993), 1779–1787.
77. Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T.I., Donahoe, J.S., Courties, G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nature Biotechnology 29 (2011), 1005–1010, 10.1038/nbt.1989 (nbt.1989 [pii]).
78. Libby, P., Maroko, P.R., Bloor, C.M., Sobel, B.E., Braunwald, E., Reduction of experimental myocardial infarct size by corticosteroid administration. The Journal of Clinical Investigation 52 (1973), 599–607, 10.1172/JCI107221.
79. Liu, H., Gao, W., Yuan, J., Wu, C., Yao, K., Zhang, L., et al. Exosomes derived from dendritic cells improve cardiac function via activation of CD4(+) T lymphocytes after myocardial infarction. Journal of Molecular and Cellular Cardiology 91 (2016), 123–133, 10.1016/j.yjmcc.2015.12.028 (S0022-2828(15)30166-8 [pii]).
80. Ma, Y., Yabluchanskiy, A., Iyer, R.P., Cannon, P.L., Flynn, E.R., Jung, M., et al. Temporal neutrophil polarization following myocardial infarction. Cardiovascular Research 110 (2016), 51–61, 10.1093/cvr/cvw024 (cvw024 [pii]).
81. Mahaffey, K.W., Granger, C.B., Nicolau, J.C., Ruzyllo, W., Weaver, W.D., Theroux, P., et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108 (2003), 1176–1183.
82. Mantovani, A., Cassatella, M.A., Costantini, C., Jaillon, S., Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Reviews Immunology 11 (2011), 519–531, 10.1038/nri3024 (nri3024 [pii]).
83. Marchetti, C., Chojnacki, J., Toldo, S., Mezzaroma, E., Tranchida, N., Rose, S.W., et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. Journal of Cardiovascular Pharmacology 63 (2014), 316–322, 10.1097/FJC.0000000000000053.
84. Marek-Trzonkowska, N., Mysliwiec, M., Dobyszuk, A., Grabowska, M., Derkowska, I., Juscinska, J., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets — results of one year follow-up. Clinical Immunology 153 (2014), 23–30, 10.1016/j.clim.2014.03.016 (S1521-6616(14)00080-1 [pii]).
85. Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 (2006), 228–232, 10.1038/nature04515 (nature04515 [pii]).
86. Martel, C., Granger, C.B., Ghitescu, M., Stebbins, A., Fortier, A., Armstrong, P.W., et al. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal 164 (2012), 43–51, 10.1016/j.ahj.2012.04.007 (S0002-8703(12)00291-8 [pii]).
87. Matsumoto, K., Ogawa, M., Suzuki, J., Hirata, Y., Nagai, R., Isobe, M., Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. International Heart Journal 52 (2011), 382–387 (JST.JSTAGE/ihj/52.382 [pii]).
88. Meng, X., Yang, J., Dong, M., Zhang, K., Tu, E., Gao, Q., et al. Regulatory T cells in cardiovascular diseases. Nature Reviews Cardiology 13 (2016), 167–179, 10.1038/nrcardio.2015.169 (nrcardio.2015.169 [pii]).
89. Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I.M., Van Tassell, B.W., Salloum, F.N., et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proceedings of the National Academy of Sciences of the United States of America 108 (2011), 19725–19730, 10.1073/pnas.1108586108 (1108586108 [pii]).
90. Montecucco, F., Braunersreuther, V., Lenglet, S., Delattre, B.M., Pelli, G., Buatois, V., et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. European Heart Journal 33 (2012), 1964–1974, 10.1093/eurheartj/ehr127 (ehr127 [pii]).
91. Montecucco, F., Lenglet, S., Braunersreuther, V., Pelli, G., Pellieux, C., Montessuit, C., et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 30 (2010), 1371–1377, 10.1161/ATVBAHA.110.206011 (ATVBAHA.110.206011 [pii]).
92. Mor, A., Luboshits, G., Planer, D., Keren, G., George, J., Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. European Heart Journal 27 (2006), 2530–2537, 10.1093/eurheartj/ehl222 (ehl222 [pii]).
93. Morton, A.C., Rothman, A.M., Greenwood, J.P., Gunn, J., Chase, A., Clarke, B., et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study. European Heart Journal 36 (2015), 377–384, 10.1093/eurheartj/ehu272 (ehu272 [pii]).
94. Mullane, K., Engler, R., Proclivity of activated neutrophils to cause postischemic cardiac dysfunction: Participation in stunning?. Cardiovascular Drugs and Therapy 5 (1991), 915–923.
95. Naftali-Shani, N., Levin-Kotler, L.P., Palevski, D., Amit, U., Kain, D., Landa, N., et al. Left ventricular dysfunction switches mesenchymal stromal cells toward an inflammatory phenotype and impairs their reparative properties via toll-like Receptor-4. Circulation 135 (2017), 2271–2287, 10.1161/CIRCULATIONAHA.116.023527 (CIRCULATIONAHA.116.023527 [pii]).
96. Nahrendorf, M., Pittet, M.J., Swirski, F.K., Monocytes: Protagonists of infarct inflammation and repair after myocardial infarction. Circulation 121 (2010), 2437–2445, 10.1161/CIRCULATIONAHA.109.916346 (121/22/2437 [pii]).
97. Nahrendorf, M., Swirski, F.K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.L., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. The Journal of Experimental Medicine 204 (2007), 3037–3047, 10.1084/jem.20070885 (jem.20070885 [pii]).
98. Ono, K., Matsumori, A., Shioi, T., Furukawa, Y., Sasayama, S., Cytokine gene expression after myocardial infarction in rat hearts: Possible implication in left ventricular remodeling. Circulation 98 (1998), 149–156.
99. Orn, S., Ueland, T., Manhenke, C., Sandanger, O., Godang, K., Yndestad, A., et al. Increased interleukin-1beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Journal of Internal Medicine 272 (2012), 267–276, 10.1111/j.1365-2796.2012.02517.x.
100. Ortega-Gomez, A., Perretti, M., Soehnlein, O., Resolution of inflammation: An integrated view. EMBO Molecular Medicine 5 (2013), 661–674, 10.1002/emmm.201202382.
101. Oyama, J., Blais, C. Jr., Liu, X., Pu, M., Kobzik, L., Kelly, R.A., et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109 (2004), 784–789, 10.1161/01.CIR.0000112575.66565.84 (109/6/784 [pii]).
102. Park, J.S., Svetkauskaite, D., He, Q., Kim, J.Y., Strassheim, D., Ishizaka, A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. The Journal of Biological Chemistry 279 (2004), 7370–7377, 10.1074/jbc.M306793200 (M306793200 [pii]).
103. Pomerantz, B.J., Reznikov, L.L., Harken, A.H., Dinarello, C.A., Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proceedings of the National Academy of Sciences of the United States of America 98 (2001), 2871–2876, 10.1073/pnas.041611398 (98/5/2871 [pii]).
104. Prabhu, S.D., Frangogiannis, N.G., The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circulation Research 119 (2016), 91–112, 10.1161/CIRCRESAHA.116.303577 (CIRCRESAHA.116.303577 [pii]).
105. Preissner, K.T., Boisvert, W.A., Hausenloy, D.J., Surfing on the cardiovascular frontier wave. Thrombosis and Haemostasis 113 (2015), 439–440, 10.1160/TH15-01-0086 (15-01-0086 [pii]).
106. Reilly, M., Miller, R.M., Thomson, M.H., Patris, V., Ryle, P., McLoughlin, L., et al. Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody. Clinical Pharmacology and Therapeutics 94 (2013), 593–600, 10.1038/clpt.2013.150 (clpt2013150 [pii]).
107. Ritter, L.S., Wilson, D.S., Williams, S.K., Copeland, J.G., McDonagh, P.F., Early in reperfusion following myocardial ischemia, leukocyte activation is necessary for venular adhesion but not capillary retention. Microcirculation 2 (1995), 315–327.
108. Sandanger, O., Ranheim, T., Vinge, L.E., Bliksoen, M., Alfsnes, K., Finsen, A.V., et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovascular Research 99 (2013), 164–174, 10.1093/cvr/cvt091 (cvt091 [pii]).
109. Sardella, G., De, L.L., Francavilla, V., Accapezzato, D., Mancone, M., Sirinian, M.I., et al. Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. Thrombosis Research 120 (2007), 631–634, 10.1016/j.thromres.2006.12.005 (S0049-3848(06)00511-1 [pii]).
110. Saxena, A., Dobaczewski, M., Rai, V., Haque, Z., Chen, W., Li, N., et al. Regulatory T cells are recruited in the infarcted mouse myocardium and may modulate fibroblast phenotype and function. American Journal of Physiology. Heart and Circulatory Physiology 307 (2014), H1233–H1242, 10.1152/ajpheart.00328.2014 (ajpheart.00328.2014 [pii]).
111. Seok, J., Warren, H.S., Cuenca, A.G., Mindrinos, M.N., Baker, H.V., Xu, W., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 3507–3512, 10.1073/pnas.1222878110 (1222878110 [pii]).
112. Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology 8 (2008), 349–361, 10.1038/nri2294 (nri2294 [pii]).
113. Shimamoto, A., Chong, A.J., Yada, M., Shomura, S., Takayama, H., Fleisig, A.J., et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114 (2006), I270–I274, 10.1161/CIRCULATIONAHA.105.000901 (114/1_suppl/I-270 [pii]).
114. Shinde, A.V., Frangogiannis, N.G., Fibroblasts in myocardial infarction: A role in inflammation and repair. Journal of Molecular and Cellular Cardiology 70 (2014), 74–82, 10.1016/j.yjmcc.2013.11.015 (S0022-2828(13)00347-7 [pii]).
115. Shishido, T., Nozaki, N., Yamaguchi, S., Shibata, Y., Nitobe, J., Miyamoto, T., et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108 (2003), 2905–2910, 10.1161/01.CIR.0000101921.93016.1C (01.CIR.0000101921.93016.1C [pii]).
116. Sobirin, M.A., Kinugawa, S., Takahashi, M., Fukushima, A., Homma, T., Ono, T., et al. Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circulation Research 111 (2012), 1037–1047, 10.1161/CIRCRESAHA.112.270132 (CIRCRESAHA.112.270132 [pii]).
117. Stieger, P., Daniel, J.M., Tholen, C., Dutzmann, J., Knopp, K., Gunduz, D., et al. Targeting of extracellular RNA reduces edema formation and infarct size and improves survival after myocardial infarction in mice. Journal of the American Heart Association, 6, 2017, 10.1161/JAHA.116.004541 (JAHA.116.004541 [pii]).
118. Suematsu, M., DeLano, F.A., Poole, D., Engler, R.L., Miyasaka, M., Zweifach, B.W., et al. Spatial and temporal correlation between leukocyte behavior and cell injury in postischemic rat skeletal muscle microcirculation. Laboratory Investigation 70 (1994), 684–695.
119. Swerdlow, D.I., Holmes, M.V., Kuchenbaecker, K.B., Engmann, J.E., Shah, T., Sofat, R., et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A Mendelian randomisation analysis. Lancet 379 (2012), 1214–1224, 10.1016/S0140-6736(12)60110-X (S0140-6736(12)60110-X [pii]).
120. Takahashi, K., Fukushima, S., Yamahara, K., Yashiro, K., Shintani, Y., Coppen, S.R., et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 118 (2008), S106–S114, 10.1161/CIRCULATIONAHA.107.757443 (118/14_suppl_1/S106 [pii]).
121. Tanaka, M., Brooks, S.E., Richard, V.J., FitzHarris, G.P., Stoler, R.C., Jennings, R.B., et al. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 87 (1993), 526–535.
122. Tang, T.T., Yuan, J., Zhu, Z.F., Zhang, W.C., Xiao, H., Xia, N., et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Research in Cardiology, 107, 2012, 232, 10.1007/s00395-011-0232-6.
123. Tardif, J.C., Tanguay, J.F., Wright, S.R., Duchatelle, V., Petroni, T., Gregoire, J.C., et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: Results of the SELECT-ACS trial. Journal of the American College of Cardiology 61 (2013), 2048–2055, 10.1016/j.jacc.2013.03.003 (S0735-1097(13)00928-5 [pii]).
124. ter Horst, E.N., Hakimzadeh, N., van der Laan, A.M., Krijnen, P.A., Niessen, H.W., Piek, J.J., Modulators of macrophage polarization influence healing of the infarcted myocardium. International Journal of Molecular Sciences 16 (2015), 29583–29591, 10.3390/ijms161226187 (ijms161226187 [pii]).
125. Thielmann, M., Marggraf, G., Neuhauser, M., Forkel, J., Herold, U., Kamler, M., et al. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. European Journal of Cardio-Thoracic Surgery 30 (2006), 285–293, 10.1016/j.ejcts.2006.04.022 (S1010-7940(06)00451-9 [pii]).
126. Timmers, L., Pasterkamp, G., de Hoog, V.C., Arslan, F., Appelman, Y., de Kleijn, D.P., The innate immune response in reperfused myocardium. Cardiovascular Research 94 (2012), 276–283, 10.1093/cvr/cvs018 (cvs018 [pii]).
127. Timmers, L., Sluijter, J.P., van Keulen, J.K., Hoefer, I.E., Nederhoff, M.G., Goumans, M.J., et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circulation Research 102 (2008), 257–264, 10.1161/CIRCRESAHA.107.158220 (CIRCRESAHA.107.158220 [pii]).
128. Toldo, S., Marchetti, C., Mauro, A.G., Chojnacki, J., Mezzaroma, E., Carbone, S., et al. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. International Journal of Cardiology 209 (2016), 215–220, 10.1016/j.ijcard.2016.02.043 (S0167-5273(16)30259-5 [pii]).
129. Trzonkowski, P., Bieniaszewska, M., Juscinska, J., Dobyszuk, A., Krzystyniak, A., Marek, N., et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+C. Clinical Immunology 133 (2009), 22–26, 10.1016/j.clim.2009.06.001 (S1521-6616(09)00697-4 [pii]).
130. Vakeva, A.P., Agah, A., Rollins, S.A., Matis, L.A., Li, L., Stahl, G.L., Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97 (1998), 2259–2267.
131. van der Pals, J., Koul, S., Andersson, P., Gotberg, M., Ubachs, J.F., Kanski, M., et al. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovascular Disorders, 10, 2010, 45, 10.1186/1471-2261-10-45 (1471-2261-10-45 [pii]).
132. van Hout, G.P., Arslan, F., Pasterkamp, G., Hoefer, I.E., Targeting danger-associated molecular patterns after myocardial infarction. Expert Opinion on Therapeutic Targets 20 (2016), 223–239, 10.1517/14728222.2016.1088005.
133. Varda-Bloom, N., Leor, J., Ohad, D.G., Hasin, Y., Amar, M., Fixler, R., et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. Journal of Molecular and Cellular Cardiology 32 (2000), 2141–2149, 10.1006/jmcc.2000.1261 (S0022-2828(00)91261-6 [pii]).
134. Verrier, E.D., Shernan, S.K., Taylor, K.M., Van De, W.F., Newman, M.F., Chen, J.C., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. Journal of the American Medical Association 291 (2004), 2319–2327.
135. Volz, H.C., Laohachewin, D., Seidel, C., Lasitschka, F., Keilbach, K., Wienbrandt, A.R., et al. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-kappaB signaling. Basic Research in Cardiology, 107, 2012, 250, 10.1007/s00395-012-0250-z.
136. Walsh, M.C., Bourcier, T., Takahashi, K., Shi, L., Busche, M.N., Rother, R.P., et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. Journal of Immunology 175 (2005), 541–546 (175/1/541 [pii]).
137. Wang, Y.M., Alexander, S.I., IL-2/anti-IL-2 complex: A novel strategy of in vivo regulatory T cell expansion in renal injury. Journal of the American Society of Nephrology 24 (2013), 1503–1504, 10.1681/ASN.2013070718 (ASN.2013070718 [pii]).
138. Wang, G., Kim, R.Y., Imhof, I., Honbo, N., Luk, F.S., Li, K., et al. The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. Journal of Cardiovascular Pharmacology 63 (2014), 132–143, 10.1097/FJC.0000000000000031.
139. Wang, Y.P., Xie, Y., Ma, H., Su, S.A., Wang, Y.D., Wang, J.A., et al. Regulatory T lymphocytes in myocardial infarction: A promising new therapeutic target. International Journal of Cardiology 203 (2016), 923–928, 10.1016/j.ijcard.2015.11.078 (S0167-5273(15)30887-1 [pii]).
140. Warren, H.S., Fitting, C., Hoff, E., Adib-Conquy, M., Beasley-Topliffe, L., Tesini, B., et al. Resilience to bacterial infection: Difference between species could be due to proteins in serum. The Journal of Infectious Diseases 201 (2010), 223–232, 10.1086/649557.
141. Weirather, J., Hofmann, U.D., Beyersdorf, N., Ramos, G.C., Vogel, B., Frey, A., et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circulation Research 115 (2014), 55–67, 10.1161/CIRCRESAHA.115.303895 (CIRCRESAHA.115.303895 [pii]).
142. Weisman, H.F., Bartow, T., Leppo, M.K., Marsh, H.C. Jr., Carson, G.R., Concino, M.F., et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990), 146–151.
143. Westman, P.C., Lipinski, M.J., Luger, D., Waksman, R., Bonow, R.O., Wu, E., et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. Journal of the American College of Cardiology 67 (2016), 2050–2060, 10.1016/j.jacc.2016.01.073 (S0735-1097(16)00822-6 [pii]).
144. Wigren, M., Bjorkbacka, H., Andersson, L., Ljungcrantz, I., Fredrikson, G.N., Persson, M., et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arteriosclerosis, Thrombosis, and Vascular Biology 32 (2012), 2000–2004, 10.1161/ATVBAHA.112.251579 (ATVBAHA.112.251579 [pii]).
145. Yan, X., Anzai, A., Katsumata, Y., Matsuhashi, T., Ito, K., Endo, J., et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. Journal of Molecular and Cellular Cardiology 62 (2013), 24–35, 10.1016/j.yjmcc.2013.04.023 (S0022-2828(13)00164-8 [pii]).
146. Yellon, D.M., Hausenloy, D.J., Myocardial reperfusion injury. The New England Journal of Medicine 357 (2007), 1121–1135.
147. Zernecke, A., Preissner, K.T., Extracellular ribonucleic acids (RNA) enter the stage in cardiovascular disease. Circulation Research 118 (2016), 469–479, 10.1161/CIRCRESAHA.115.307961 (CIRCRESAHA.115.307961 [pii]).
148. Zhang, H., Qin, G., Liang, G., Li, J., Barrington, R.A., Liu, D.X., C5aR-mediated myocardial ischemia/reperfusion injury. Biochemical and Biophysical Research Communications 357 (2007), 446–452, 10.1016/j.bbrc.2007.03.152 (S0006-291X(07)00653-5 [pii]).
149. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 (2010), 104–107, 10.1038/nature08780 (nature08780 [pii]).
150. Zhang, W.C., Wang, J., Shu, Y.W., Tang, T.T., Zhu, Z.F., Xia, N., et al. Impaired thymic export and increased apoptosis account for regulatory T cell defects in patients with non-ST segment elevation acute coronary syndrome. The Journal of Biological Chemistry 287 (2012), 34157–34166, 10.1074/jbc.M112.382978 (M112.382978 [pii]).
151. Zhao, Z.Q., Nakamura, M., Wang, N.P., Wilcox, J.N., Shearer, S., Ronson, R.S., et al. Reperfusion induces myocardial apoptotic cell death. Cardiovascular Research 45 (2000), 651–660.
152. Zhao, Z.Q., Velez, D.A., Wang, N.P., Hewan-Lowe, K.O., Nakamura, M., Guyton, R.A., et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 6 (2001), 279–290.
153. Zhou, L.S., Zhao, G.L., Liu, Q., Jiang, S.C., Wang, Y., Zhang, D.M., Silencing collapsin response mediator protein-2 reprograms macrophage phenotype and improves infarct healing in experimental myocardial infarction model. Journal of Inflammation (London), 12, 2015, 11, 10.1186/s12950-015-0053-8 (53 [pii]).
154. Zouggari, Y., Ait-Oufella, H., Bonnin, P., Simon, T., Sage, A.P., Guerin, C., et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nature Medicine 19 (2013), 1273–1280, 10.1038/nm.3284 (nm.3284 [pii]).